According to clinical trial supported by the Ethics Committee of Hospital Puerta del Hierro (Madrid), AB-life reduces total cholesterol levels between 14% and 18%. AB-Life will be released in the next six months in the Korean market.
Miquel Angel Bonachera and Sergi Audivert, co-founders and CEOs of AB-Biotics, said: “This contract marks a significant milestone for AB-Biotics, since Korea opens the Asian door for our international expansion, and thanks to HanAll BioPharma we can enter there with a local and very well positioned partnership.”
Source: AB-Biotics
© FoodBev Media Ltd 2024